References
Key articles
National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. January 2024 [internet publication].Full text
Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. September 2023 [internet publication].Full text
Yelin D, Moschopoulos CD, Margalit I, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022 Jul;28(7):955-72.Full text Abstract
US Department of Veterans Affairs. Whole health system approach to long COVID. August 2022 [internet publication].Full text
Reference articles
1. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. January 2024 [internet publication].Full text
2. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. October 2021 [internet publication].Full text
3. World Health Organization. Clinical management of COVID-19: living guideline. August 2023 [internet publication].Full text
4. Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. September 2023 [internet publication].Full text
5. Del Rio C, Malani PN. COVID-19-New Insights on a Rapidly Changing Epidemic. JAMA. 2020 Apr 14;323(14):1339-40.Full text Abstract
6. Greenhalgh T, Knight M, A'Court C, et al. Management of post-acute covid-19 in primary care. BMJ. 2020 Aug 11;370:m3026.Full text Abstract
7. Rubin R. As their numbers grow, COVID-19 "long haulers" stump experts. JAMA. 2020 Oct 13;324(14):1381-3.Full text Abstract
8. Thaweethai T, Jolley SE, Karlson EW, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023 Jun 13;329(22):1934-46.Full text Abstract
9. Zhang H, Zang C, Xu Z, et al. Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat Med. 2023 Jan;29(1):226-35.Full text Abstract
10. Global Burden of Disease Long COVID Collaborators, Wulf Hanson S, Abbafati C, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022 Oct 25;328(16):1604-15.Full text Abstract
11. Pfaff ER, Girvin AT, Bennett TD, et al. Identifying who has long COVID in the USA: a machine learning approach using N3C data. Lancet Digit Health. 2022 Jul;4(7):e532-e541.Full text Abstract
12. Estiri H, Strasser ZH, Brat GA, et al. Evolving phenotypes of non-hospitalized patients that indicate long covid. medRxiv. 2021 Jul 10:2021.04.25.21255923.Full text Abstract
13. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021 Aug;38:101019.Full text Abstract
14. Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, et al. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis. Eur J Intern Med. 2021 Oct;92:55-70.Full text Abstract
15. Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute Ssequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021 Oct 1;4(10):e2128568.Full text Abstract
16. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021 Apr;27(4):626-31.Full text Abstract
17. Office for National Statistics. Technical article: updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021. September 2021 [internet publication].Full text
18. Ballering AV, van Zon SKR, Olde Hartman TC, et al. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022 Aug 6;400(10350):452-61.Full text Abstract
19. Wu X, Liu X, Zhou Y, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021 Jul;9(7):747-54.Full text Abstract
20. Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021 Aug 28;398(10302):747-58.Full text Abstract
21. Huang L, Li X, Gu X, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022 Sep;10(9):863-76.Full text Abstract
22. Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022 Aug;28(8):1706-14.Full text Abstract
23. Augustin M, Schommers P, Stecher M, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021 Jul;6:100122.Full text Abstract
24. Havervall S, Rosell A, Phillipson M, et al. Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA. 2021 May 18;325(19):2015-6.Full text Abstract
25. Stavem K, Ghanima W, Olsen MK, et al. Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax. 2021 Apr;76(4):405-7.Full text Abstract
26. Ma Y, Deng J, Liu Q, et al. Long-term consequences of asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis. Int J Environ Res Public Health. 2023 Jan 16;20(2):1613.Full text Abstract
27. Lopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. Sci Rep. 2022 Jun 23;12(1):9950.Full text Abstract
28. Pellegrino R, Chiappini E, Licari A, et al. Prevalence and clinical presentation of long COVID in children: a systematic review. Eur J Pediatr. 2022 Dec;181(12):3995-4009.Full text Abstract
29. Notarte KI, Catahay JA, Velasco JV, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. EClinicalMedicine. 2022 Nov;53:101624.Full text Abstract
30. Antonelli M, Pujol JC, Spector TD, et al. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022 Jun 18;399(10343):2263-4.Full text Abstract
31. Fernández-de-Las-Peñas C, Notarte KI, Peligro PJ, et al. Long-COVID symptoms in individuals infected with different SARS-CoV-2 variants of concern: a systematic review of the literature. Viruses. 2022 Nov 25;14(12):2629.Full text Abstract
32. Davis HE, McCorkell L, Vogel JM, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023 Mar;21(3):133-46.Full text Abstract
33. Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-8.Full text Abstract
34. Aiyegbusi OL, Hughes SE, Turner G, et al. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021 Sep;114(9):428-42.Full text Abstract
35. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022 Jan;22(1):43-55.Full text Abstract
36. Crook H, Raza S, Nowell J, et al. Long covid-mechanisms, risk factors, and management. BMJ. 2021 Jul 26;374:n1648. Abstract
37. Kamal M, Abo Omirah M, Hussein A, et al. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract. 2021 Mar;75(3):e13746. Abstract
38. Sneller MC, Liang CJ, Marques AR, et al. A longitudinal study of COVID-19 sequelae and immunity: baseline findings. Ann Intern Med. 2022 Jul;175(7):969-79.Full text Abstract
39. Herman E, Shih E, Cheng A. Long COVID: rapid evidence review. Am Fam Physician. 2022 Nov;106(5):523-32. Abstract
40. Azzolini E, Levi R, Sarti R, et al. Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA. 2022 Aug 16;328(7):676-8.Full text Abstract
41. Wang S, Quan L, Chavarro JE, et al. Associations of depression, anxiety, worry, perceived stress, and loneliness prior to infection with risk of post-COVID-19 conditions. JAMA Psychiatry. 2022 Nov 1;79(11):1081-91.Full text Abstract
42. Tsampasian V, Elghazaly H, Chattopadhyay R, et al. Risk factors associated with post-COVID-19 condition: a systematic review and meta-analysis. JAMA Intern Med. 2023 Jun 1;183(6):566-80.Full text Abstract
43. Maglietta G, Diodati F, Puntoni M, et al. Prognostic factors for post-COVID-19 syndrome: a systematic review and meta-analysis. J Clin Med. 2022 Mar 11;11(6):1541.Full text Abstract
44. Xie Y, Choi T, Al-Aly Z. Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study. Lancet Infect Dis. 2023 Dec 14:S1473-3099(23)00684-9.Full text Abstract
45. Klein J, Wood J, Jaycox JR, et al. Distinguishing features of long COVID identified through immune profiling. Nature. 2023 Nov;623(7985):139-48.Full text Abstract
46. Glynne P, Tahmasebi N, Gant V, et al. Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines. J Investig Med. 2022 Jan;70(1):61-7.Full text Abstract
47. Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022 Feb;23(2):210-6.Full text Abstract
48. Schultheiß C, Willscher E, Paschold L, et al. The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med. 2022 Jun 21;3(6):100663.Full text Abstract
49. Peluso MJ, Lu S, Tang AF, et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. 2021 Dec 1;224(11):1839-48.Full text Abstract
50. Wallukat G, Hohberger B, Wenzel K, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100.Full text Abstract
51. Arthur JM, Forrest JC, Boehme KW, et al. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS One. 2021 Sep 3;16(9):e0257016.Full text Abstract
52. Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022 Mar 3;185(5):881-95.e20.Full text Abstract
53. Wong AC, Devason AS, Umana IC, et al. Serotonin reduction in post-acute sequelae of viral infection. Cell. 2023 Oct 26;186(22):4851-67.e20.Full text Abstract
54. Siripanthong B, Asatryan B, Hanff TC, et al. The pathogenesis and long-term consequences of COVID-19 cardiac injury. JACC Basic Transl Sci. 2022 Mar;7(3):294-308.Full text Abstract
55. Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. Trends Immunol. 2022 Apr;43(4):268-70.Full text Abstract
56. Fogarty H, Townsend L, Morrin H, et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost. 2021 Oct;19(10):2546-53.Full text Abstract
57. Clark IA. Chronic cerebral aspects of long COVID, post-stroke syndromes and similar states share their pathogenesis and perispinal etanercept treatment logic. Pharmacol Res Perspect. 2022 Apr;10(2):e00926.Full text Abstract
58. Thompson RC, Simons NW, Wilkins L, et al. Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae. Nat Med. 2023 Jan;29(1):236-46.Full text Abstract
59. Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021 Aug 23;20(1):172.Full text Abstract
60. Liptak P, Baranovicova E, Rosolanka R, et al. Persistence of metabolomic changes in patients during post-COVID phase: a prospective, observational study. Metabolites. 2022 Jul 13;12(7):641.Full text Abstract
61. Goh D, Lim JCT, Fernaíndez SB, et al. Case report: Persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID. Front Immunol. 2022 Sep 5:13:939989.Full text Abstract
62. Xie Y, Choi T, Al-Aly Z. Nirmatrelvir and the risk of post-acute sequelae of COVID-19. medRxiv 2022 [preprint publication].Full text
63. Hedberg P, Granath F, Bruchfeld J, et al. Post COVID-19 condition diagnosis: a population-based cohort study of occurrence, associated factors, and healthcare use by severity of acute infection. J Intern Med. 2023 Feb;293(2):246-58.Full text Abstract
64. Català M, Mercadé-Besora N, Kolde R, et al. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir Med. 2024 Jan 11:S2213-2600(23)00414-9.Full text Abstract
65. Florencio LL, Fernández-de-Las-Peñas C. Long COVID: systemic inflammation and obesity as therapeutic targets. Lancet Respir Med. 2022 Aug;10(8):726-7.Full text Abstract
66. Al-Aly Z. Prevention of long COVID: progress and challenges. Lancet Infect Dis. 2023 Jul;23(7):776-7.Full text Abstract
67. Ayoubkhani D, Bermingham C, Pouwels KB, et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ. 2022 May 18;377:e069676.Full text Abstract
68. Arnold DT, Milne A, Samms E, et al. Symptoms after COVID-19 vaccination in patients with persistent symptoms after acute infection: a case series. Ann Intern Med. 2021 Sep;174(9):1334-6.Full text Abstract
69. Whittaker HR, Gulea C, Koteci A, et al. GP consultation rates for sequelae after acute covid-19 in patients managed in the community or hospital in the UK: population based study. BMJ. 2021 Dec 29;375:e065834.Full text Abstract
70. Wisnivesky JP, Govindarajulu U, Bagiella E, et al. Association of vaccination with the persistence of post-COVID symptoms. J Gen Intern Med. 2022 May;37(7):1748-53.Full text Abstract
71. Richard SA, Pollett SD, Fries AC, et al. Persistent COVID-19 symptoms at 6 months after onset and the role of vaccination before or after SARS-CoV-2 infection. JAMA Netw Open. 2023 Jan 3;6(1):e2251360.Full text Abstract
72. Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med. 2023 Jun 1;183(6):554-64.Full text Abstract
73. Xie Y, Choi T, Al-Aly Z. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. BMJ. 2023 Apr 25;381:e074572.Full text Abstract
74. Suran M. VA finds Nirmatrelvir associated with lower risk of long COVID. JAMA. 2022 Dec 27;328(24):2386.Full text Abstract
75. Boglione L, Meli G, Poletti F, et al. Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? QJM. 2022 Jan 9;114(12):865-71.Full text Abstract
76. Nevalainen OPO, Horstia S, Laakkonen S, et al. Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial. Nat Commun. 2022 Oct 18;13(1):6152.Full text Abstract
77. Durstenfeld MS, Peluso MJ, Lin F, et al. Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study. J Med Virol. 2024 Jan;96(1):e29333.Full text Abstract
78. Greenhalgh T, Sivan M, Delaney B, et al. Long covid-an update for primary care. BMJ. 2022 Sep 22;378:e072117.Full text Abstract
79. O'Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of long COVID among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2023 Jan;55:101762.Full text Abstract
80. Yelin D, Moschopoulos CD, Margalit I, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022 Jul;28(7):955-72.Full text Abstract
81. Whiteson JH, Azola A, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jul;14(7):855-78. Abstract
82. Herrera JE, Niehaus WN, Whiteson J, et al. Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of fatigue in postacute sequelae of SARS-CoV-2 infection (PASC) patients. PM R. 2021 Sep;13(9):1027-43. Abstract
83. Maley JH, Alba GA, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of breathing discomfort and respiratory sequelae in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jan;14(1):77-95.Full text Abstract
84. Munblit D, Nicholson T, Akrami A, et al. A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. Lancet Respir Med. 2022 Jul;10(7):715-24.Full text Abstract
85. Mikkelsen ME, Still M, Anderson BJ, et al. Society of Critical Care Medicine's international consensus conference on prediction and identification of long-term impairments after critical illness. Crit Care Med. 2020 Nov;48(11):1670-9. Abstract
86. Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021 Sep;6(9):e005427.Full text Abstract
87. Blitshteyn S, Whiteson JH, Abramoff B, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of autonomic dysfunction in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Oct;14(10):1270-91. Abstract
88. US Department of Veterans Affairs. Whole health system approach to long COVID. August 2022 [internet publication].Full text
89. So M, Kabata H, Fukunaga K, et al. Radiological and functional lung sequelae of COVID-19: a systematic review and meta-analysis. BMC Pulm Med. 2021 Mar 22;21(1):97.Full text Abstract
90. Watanabe A, So M, Iwagami M, et al. One-year follow-up CT findings in COVID-19 patients: a systematic review and meta-analysis. Respirology. 2022 Aug;27(8):605-16.Full text Abstract
91. Bocchino M, Rea G, Capitelli L, et al. Chest CT lung abnormalities 1 year after COVID-19: a systematic review and meta-analysis. Radiology. 2023 Jul;308(1):e230535.Full text Abstract
92. Fine JS, Ambrose AF, Didehbani N, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cognitive symptoms in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022 Jan;14(1):96-111.Full text Abstract
93. Mueller MR, Ganesh R, Hurt RT, et al. Post-COVID conditions. Mayo Clin Proc. 2023 Jul;98(7):1071-8.Full text Abstract
94. Melamed E, Rydberg L, Ambrose AF, et al. Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of neurologic sequelae in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2023 May;15(5):640-62.Full text Abstract
95. Whitaker M, Elliott J, Chadeau-Hyam M, et al. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun. 2022 Apr 12;13(1):1957.Full text Abstract
96. Oaklander AL, Mills AJ, Kelley M, et al. Peripheral neuropathy evaluations of patients with prolonged long COVID. Neurol Neuroimmunol Neuroinflamm. 2022 May;9(3):e1146.Full text Abstract
97. Nguyen B, Tosti A. Alopecia in patients with COVID-19: a systematic review and meta-analysis. JAAD Int. 2022 Jun;7:67-77.Full text Abstract
98. Marasco G, Cremon C, Barbaro MR, et al. Post COVID-19 irritable bowel syndrome. Gut. 2022 Dec 9:gutjnl-2022-328483.Full text Abstract
99. Clayton EW. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: an IOM report on redefining an illness. JAMA. 2015 Mar 17;313(11):1101-2. Abstract
100. Wong TL, Weitzer DJ. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) -a systemic review and comparison of clinical presentation and symptomatology. Medicina (Kaunas). 2021 Apr 26;57(5):418.Full text Abstract
101. Heesakkers H, van der Hoeven JG, Corsten S, et al. Clinical outcomes among patients with 1-year survival following intensive care unit treatment for COVID-19. JAMA. 2022 Feb 8;327(6):559-65.Full text Abstract
102. Martillo MA, Dangayach NS, Tabacof L, et al. Postintensive care syndrome in survivors of critical illness related to coronavirus disease 2019: cohort study from a New York City critical care recovery clinic. Crit Care Med. 2021 Sep 1;49(9):1427-38.Full text Abstract
103. Morelli N, Parry SM, Steele A, et al. Patients surviving critical COVID-19 have impairments in dual-task performance related to post-intensive care syndrome. J Intensive Care Med. 2022 Jul;37(7):890-8.Full text Abstract
104. Núñez-Seisdedos MN, Lázaro-Navas I, López-González L, et al. Intensive care unit-acquired weakness and hospital functional mobility outcomes following invasive mechanical ventilation in patients with COVID-19: a single-centre prospective cohort study. J Intensive Care Med. 2022 Aug;37(8):1005-14.Full text Abstract
105. Neville TH, Hays RD, Tseng CH, et al. Survival after severe COVID-19: long-term outcomes of patients admitted to an intensive care unit. J Intensive Care Med. 2022 Aug;37(8):1019-28.Full text Abstract
106. Hodgson CL, Higgins AM, Bailey MJ, et al. Comparison of 6-month outcomes of survivors of COVID-19 versus non-COVID-19 critical illness. Am J Respir Crit Care Med. 2022 May 15;205(10):1159-68.Full text Abstract
107. Kavi L, Gammage MD, Grubb BP, et al. Postural tachycardia syndrome: multiple symptoms, but easily missed. Br J Gen Pract. 2012 Jun;62(599):286-7.Full text Abstract
108. Weiler CR, Austen KF, Akin C, et al. AAAAI Mast Cell Disorders Committee work group report: mast cell activation syndrome (MCAS) diagnosis and management. J Allergy Clin Immunol. 2019 Oct;144(4):883-96.Full text Abstract
109. Ministry of Health. Clinical rehabilitation guideline for people with long COVID (coronavirus disease) in Aotearoa New Zealand. December 2022 [internet publication].Full text
110. NHS England. After-care needs of inpatients recovering from COVID-19. June 2020 [internet publication].Full text
111. O'Kelly B, Vidal L, McHugh T, et al. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun Health. 2022 Oct;24:100485.Full text Abstract
112. Blockmans D, Persoons P, Van Houdenhove B, et al. Does methylphenidate reduce the symptoms of chronic fatigue syndrome? Am J Med. 2006 Feb;119(2):167.e23-30.Full text Abstract
113. Vance H, Maslach A, Stoneman E, et al. Addressing post-COVID symptoms: a guide for primary care physicians. J Am Board Fam Med. 2021 Nov-Dec;34(6):1229-42.Full text Abstract
114. Addison AB, Wong B, Ahmed T, et al. Clinical Olfactory Working Group consensus statement on the treatment of postinfectious olfactory dysfunction. J Allergy Clin Immunol. 2021 May;147(5):1704-19.Full text Abstract
115. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021 Apr;27(4):601-15.Full text Abstract
116. Plaut S. "Long COVID-19" and viral "fibromyalgia-ness": Suggesting a mechanistic role for fascial myofibroblasts (Nineveh, the shadow is in the fascia). Front Med (Lausanne). 2023 Apr 6;10:952278.Full text Abstract
117. Savin E, Rosenn G, Tsur AM, et al. The possible onset of fibromyalgia following acute COVID-19 infection. PLoS One. 2023;18(2):e0281593.Full text Abstract
118. Ablin J, Fitzcharles MA, Buskila D, et al. Treatment of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evid Based Complement Alternat Med. 2013;2013:485272.Full text Abstract
119. American Academy of Pediatrics. Post-COVID-19 conditions in children and adolescents. September 2022 [internet publication].Full text
120. Writing Committee, Gluckman TJ, Bhave NM, et al. 2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 May 3;79(17):1717-56.Full text Abstract
121. Antoniou KM, Vasarmidi E, Russell AM, et al. European Respiratory Society statement on long COVID follow-up. Eur Respir J. 2022 Aug;60(2):2102174.Full text Abstract
122. Servier C, Porcher R, Pane I, et al. Trajectories of the evolution of post-COVID-19 condition, up to two years after symptoms onset. Int J Infect Dis. 2023 Aug;133:67-74.Full text Abstract
123. Kubota T, Kuroda N, Sone D. Neuropsychiatric aspects of long COVID: a comprehensive review. Psychiatry Clin Neurosci. 2023 Feb;77(2):84-93.Full text Abstract
124. Hartung TJ, Neumann C, Bahmer T, et al. Fatigue and cognitive impairment after COVID-19: a prospective multicentre study. EClinicalMedicine. 2022 Nov;53:101651.Full text Abstract
125. National Center for Health Statistics. Post-COVID conditions. 2023 [internet publication].Full text
126. Mizrahi B, Sudry T, Flaks-Manov N, et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023 Jan 11;380:e072529.Full text Abstract
Use of this content is subject to our disclaimer